TL;DR
This study identifies Complement Factor Properdin (CFP) as a promising prognostic biomarker for gastric and lung cancers. Researchers found that lower CFP expression is linked to poorer patient survival and is associated with increased infiltration of key immune cells within the tumor microenvironment, suggesting CFP plays a role in immune escape.
What Problem Does This Paper Address?
Cancer prognosis and treatment remain significant challenges, particularly for highly heterogeneous and aggressive tumors like gastric and lung cancers. While the tumor microenvironment (TME) and its interplay with immune cells are known to influence cancer progression, the specific roles of certain molecules within this complex system are not fully understood. The authors aimed to investigate the expression pattern and prognostic significance of Complement Factor Properdin (CFP) in various cancers, with a specific focus on its relationship with immune cell infiltration in gastric adenocarcinoma (STAD) and lung adenocarcinoma (LUAD). This research seeks to identify new molecular targets and biomarkers that can improve diagnostic and prognostic capabilities for these cancers.
Methods
The researchers employed a multi-pronged approach using publicly available databases and experimental validation:
- Database Analysis:
- Oncomine and TIMER: Used to analyze CFP mRNA expression levels across a broad spectrum of human cancers and compare them to normal tissues. TIMER was also used to assess the correlation between CFP expression and the infiltration levels of various immune cells (B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells) by analyzing gene markers.
- PrognoScan and Kaplan-Meier Plotter: Utilized to investigate the association between CFP expression and patient survival outcomes (overall survival, first progression, post-progression survival) in different cancer types.
- UALCAN Database: Employed to examine CFP protein expression levels in various cancer types.
- GEPIA: Used for gene correlation analysis, specifically looking at the relationship between CFP and markers for B cells, macrophages, and monocytes.
- Experimental Validation:
- Immunohistochemistry (IHC): Performed on clinical tissue samples of normal and cancerous gastric and lung tissues to validate the protein expression levels of CFP observed in database analyses.
Datasets
The study utilized several large-scale, publicly available cancer databases:
- Oncomine: A comprehensive cancer-related gene expression database.
- TIMER (Tumor Immune Estimation Resource): A web server for analyzing the infiltration of immune cells in tumors.
- PrognoScan: A database for searching relationships between gene expression and patient prognosis.
- Kaplan-Meier Plotter: A tool for assessing the effect of genes on survival using large cancer sample datasets.
- UALCAN: A database for analyzing cancer proteomic data.
- GEPIA (Gene Expression Profiling Interactive Analysis): A web server for analyzing RNA sequencing expression data from TCGA and GTEx projects.
- TCGA (The Cancer Genome Atlas): A foundational dataset for cancer genomics.
- GTEx (Genotype-Tissue Expression): A dataset providing information on gene expression in various human tissues.
The study also involved the collection of human tissue specimens from patients at The Second Affiliated Hospital of Nanjing University of Chinese Medicine for immunohistochemical analysis.
Key Insights and Ideas
- CFP as a Pan-Cancer Biomarker: The study revealed that CFP expression varies significantly across different cancer types, being downregulated in many common cancers, including gastric and lung cancer, compared to normal tissues. This suggests CFP's role is not limited to a single cancer type.
- Prognostic Power in Gastric and Lung Cancers: A critical finding is that low CFP expression is consistently associated with poorer survival outcomes (overall survival, first progression, post-progression survival) in both gastric and lung adenocarcinomas. This establishes CFP as a potential independent prognostic marker.
- Immune Cell Infiltration Link: The research uncovered a significant correlation between CFP expression and the infiltration levels of various immune cells, particularly CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells, in STAD and LUAD. This points to CFP's involvement in shaping the tumor immune microenvironment.
- Role in Immune Escape: The positive correlation between low CFP expression and increased infiltration of immune cells, coupled with poorer prognosis, suggests that CFP might play a role in immune evasion. Tumors with low CFP may be better at evading immune surveillance.
- Macrophage Polarization: The study hints at CFP's potential regulatory role in macrophage polarization, with a stronger correlation observed with M2 macrophages in STAD. This is significant because TAMs (Tumor-Associated Macrophages) are key players in the TME and can influence tumor progression.
Key Results
- Expression Levels: CFP mRNA expression was found to be significantly decreased in STAD and LUAD compared to normal tissues, confirmed by both database analysis and immunohistochemistry.
- Survival Correlation: Low CFP expression was significantly associated with poorer overall survival (OS), first progression (FP), and post-progression survival (PPS) in STAD and LUAD. Specifically, in STAD, low CFP was linked to worse survival in stage 3, T3, N2, and N3.
- Immune Infiltration Correlations: In LUAD, CFP expression showed significant positive correlations with the infiltration levels of B cells (R=0.354), CD8+ T cells (R=0.18), CD4+ T cells (R=0.45), macrophages (R=0.34), neutrophils (R=0.417), and dendritic cells (R=0.445). Similar strong positive correlations were observed in STAD for CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells.
- Tumor Purity: CFP expression was significantly correlated with tumor purity across 29 tumor types.
Limitations and Future Work
The authors acknowledge several limitations:
- Reliance on Open-Access Databases: The study's complete reliance on public databases may introduce systematic bias.
- Need for Experimental Verification: While correlations were found, the study could not definitively prove that CFP affects patient survival through immune infiltration. In vivo and in vitro experiments are needed to confirm this causal link.
- mRNA vs. Protein Level: The study primarily analyzed mRNA expression, and while protein levels were assessed in some cancers (LUAD, BRCA, COAD, OV), the correlation between mRNA and protein levels in other cancers like STAD was not fully established.
- Single Cell RNA Sequencing: The authors suggest that single-cell RNA sequencing is needed for more precise verification of findings.
Future work should focus on elucidating the precise molecular mechanisms by which CFP influences immune cell recruitment and regulation within the tumor microenvironment, particularly in gastric and lung cancers. Further clinical trials and basic experiments are recommended to fully understand CFP's role in cancer progression and its potential as a therapeutic target.
Summary updated